Cargando…
Identification of an irreversible PPARγ antagonist with potent anticancer activity
Melanoma is responsible for most skin cancer deaths, and its incidence continues to rise year after year. Different treatment options have been developed for melanoma depending on the stage of the disease. Despite recent advances in immuno‐ and targeted therapies, advanced melanoma remains incurable...
Autores principales: | Peng, Youyi, Zhang, Qiang, Zielinski, Robert M., Howells, Richard D., Welsh, William J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719157/ https://www.ncbi.nlm.nih.gov/pubmed/33280279 http://dx.doi.org/10.1002/prp2.693 |
Ejemplares similares
-
Identification of Bexarotene as a PPARγ Antagonist with HDX
por: Marciano, David P., et al.
Publicado: (2015) -
Anti-inflammatory mechanisms of the vascular smooth muscle
PPARγ
por: Mukohda, Masashi, et al.
Publicado: (2021) -
Discovery of Isoquinolinoquinazolinones as a Novel Class of Potent PPARγ Antagonists with Anti-adipogenic Effects
por: Jin, Yifeng, et al.
Publicado: (2016) -
Pharmacological profiling an abundantly expressed schistosome serotonergic GPCR identifies nuciferine as a potent antagonist
por: Chan, John D., et al.
Publicado: (2016) -
The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
por: Tsukahara, Tamotsu
Publicado: (2012)